Published on September 1, 2014

In a recent move the National Pharmaceutical Pricing authority of India has fixed prices of ten combination drugs under Drugs Prices Control Order 2013. With country’s stringent policies for pricing the domestic manufacturers has decided to move to European and US market for RnD purpose. Companies like Lupin, Sun Pharma and Piramal are heading for heavy investment in foreign lands in order to add more of complex generic drugs to their product line. Further companies are upset with continuous change in the clinical trial norms and drug norms. Further Indian companies known for manufacturing generic drugs in bulk are now planning to focus on niche market. The so called advantage of being in India is no more capital advantageous. In India it takes around one year for the approval of clinical trial where as in US it takes just 28 days.

Although working in abroad countries is highly cost intensive but the end product of these companies will get direct entrance in the niche market with higher end value of drugs. With the end of this quarter all the companies are doing well and have concluded good margins for this session. Prices for most of the chemicals continued to stay at stable rate for this week.